Processing your request


please wait...

Case Page

 

Case Status:    ONGOING    
On or around 05/06/2020 (Date of last review)

Filing Date: November 22, 2019

According to the Complaint, Progenics Pharmaceuticals, Inc. is an oncology company focused on the development and commercialization of targeted medicines and artificial intelligence to find, fight and follow cancer. The Company’s pipeline includes therapeutic agents designed to precisely target cancer and prostate-specific membrane antigen targeted imaging agents for prostate cancer.

This action stems from a proposed transaction announced on October 2, 2019, pursuant to which Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., will acquire Progenics in an all-stock transaction.

On November 12, 2019, Defendants caused the Form S-4 Registration Statement (the "S-4") to be filed with the SEC in connection with the Proposed Transaction. The S-4 solicits the Company’s shareholders to vote in favor of the Proposed Transaction. The Complaint alleges that the S-4 is materially incomplete and misleading, in violation of Sections 14(a) and 20(a) of the Exchange Act.

This case was voluntarily dismissed on March 5, 2020. A related case continues under Docket 19-CV-21200 in the District of New Jersey. Plaintiff filed an amended Complaint on April 21. On April 24, this case was transferred to the Southern District of New York.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: PGNX
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Delaware
DOCKET #: 19-CV-02183
JUDGE: Hon. Maryellen Noreika
DATE FILED: 11/22/2019
CLASS PERIOD START: 10/02/2019
CLASS PERIOD END: 11/22/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Faruqi & Faruqi, LLP (Wilmington 2019)
No Document Title Filing Date
COURT: S.D. New York
DOCKET #: 20-CV-03521
JUDGE: Hon. Maryellen Noreika
DATE FILED: 05/06/2020
CLASS PERIOD START: 02/20/2020
CLASS PERIOD END: 04/21/2020
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Stull, Stull & Brody (New York)
No Document Title Filing Date
—Related District Court Filings Data is not available